Optimizing branch-duct intraductal papillary mucinous neoplasms surveillance: Data-driven dimensional grouping for risk stratification and cost-effectiveness

doi:10.3748/wjg.v32.i20.114867

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 20

This Article

(24)

(25)

(0)

(524)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. May 28, 2026; 32(20): 114867
Published online May 28, 2026. doi: 10.3748/wjg.v32.i20.114867

Table 2 Intraductal papillary mucinous neoplasms characteristics during surveillance, n (%)

IPMN characteristics during FU	n = 333
Malignant degeneration	11 (3.3)
At least one WF at enrollment	64 (19.2)
At least two WFs at enrollment	15 (4.5)
At least one WF at the end of FU	139 (41.7)
At least two WFs at the end of FU	53 (15.9)
HRS during FU	8 (2.4)
Surgery histology
Adenocarcinoma	3 (30)
IPMN HGD	4 (40)
IPMN LGD	3 (30)
EUS histology
Adenocarcinoma	4 (16.0)
IPMN HGD	1 (4.0)
IPMN LGD	14 (56.0)
Not diagnostic	6 (24.0)
Death for other reason during FU	10 (3.0)

IPMN: Intraductal papillary mucinous neoplasms; FU: Follow up; WFs: Worrisome features; HRS: High risk stigmata; EUS: Endoscopic ultrasound; HGD: High-grade dysplasia; LGD: Low-grade dysplasia.

Full Size Table

Citation: Kayali S, Dibitetto S, Busatto A, Gaiani F, Pasta A, Calabrese F, Fantasia S, Caprioli S, Luzzi AP, De Angelis CG, Savarino EV, Laghi L, Giannini EG, Marabotto E. Optimizing branch-duct intraductal papillary mucinous neoplasms surveillance: Data-driven dimensional grouping for risk stratification and cost-effectiveness. World J Gastroenterol 2026; 32(20): 114867
URL: https://www.wjgnet.com/1007-9327/full/v32/i20/114867.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i20.114867

Kayali S, Dibitetto S, Busatto A, Gaiani F, Pasta A, Calabrese F, Fantasia S, Caprioli S, Luzzi AP, De Angelis CG, Savarino EV, Laghi L, Giannini EG, Marabotto E. Optimizing branch-duct intraductal papillary mucinous neoplasms surveillance: Data-driven dimensional grouping for risk stratification and cost-effectiveness. World J Gastroenterol 2026; 32(20): 114867 [DOI: 10.3748/wjg.v32.i20.114867]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.